Lifecore Biomedical, Inc. (NASDAQ:LFCR - Get Free Report)'s share price traded down 2.1% on Wednesday . The company traded as low as $5.89 and last traded at $5.99. 235,666 shares were traded during mid-day trading, an increase of 29% from the average session volume of 182,771 shares. The stock had previously closed at $6.12.
Lifecore Biomedical Stock Performance
The firm's 50-day moving average is $6.31 and its two-hundred day moving average is $6.84. The stock has a market cap of $174.95 million, a P/E ratio of -1.72 and a beta of 0.98.
Institutional Trading of Lifecore Biomedical
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new position in shares of Lifecore Biomedical in the 1st quarter worth $57,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Lifecore Biomedical during the 1st quarter worth about $58,000. State Board of Administration of Florida Retirement System acquired a new position in shares of Lifecore Biomedical during the 1st quarter worth about $114,000. Oppenheimer Asset Management Inc. raised its position in shares of Lifecore Biomedical by 79.9% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 43,001 shares of the company's stock valued at $228,000 after acquiring an additional 19,094 shares during the period. Finally, Barclays PLC boosted its stake in Lifecore Biomedical by 244.8% during the 3rd quarter. Barclays PLC now owns 30,911 shares of the company's stock worth $233,000 after acquiring an additional 21,946 shares during the last quarter. 83.36% of the stock is owned by institutional investors.
About Lifecore Biomedical
(
Get Free Report)
Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.
Read More
Before you consider Lifecore Biomedical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lifecore Biomedical wasn't on the list.
While Lifecore Biomedical currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
